Baricitinib against severe COVID-19 : effectiveness and safety in hospitalised pretreated patients
© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis.
METHODS: This was an observational retrospective study of hospitalised patients treated with baricitinib for severe COVID-19. Outcomes were clinical improvement on an ordinal scale of 1-8 on day 1 of baricitinib compared with day 14 (where 8=death and 1=not hospitalised with no limitations of activities), overall survival, time to recovery since baricitinib treatment started (days until hospital discharge) and laboratory parameters related to COVID-19 poor prognosis. Adverse events related to baricitinib during the admission period were also reported.
RESULTS: Forty-three patients (70% men, mean age 70 years (IQR 54-79)) treated with baricitinib daily for 6 days (IQR 5-7) were included. Thirty-six patients were treated with corticosteroids (84%). Clinical improvement was 3 points (IQR 1-4) in patients on an ordinal scale of 4-6, overall survival was 100% at day 30 and day 60 with a mean time to recovery of 12 days (IQR 9-25) from start of baricitinib treatment. No adverse events of interest were found and all poor prognosis risk factors improved at day 14: interleukin-6, C-reactive protein, ferritin, lymphocytes, platelets and D-dimers.
CONCLUSIONS: Patients treated with baricitinib for severe COVID-19 showed improvements in clinical and analytical values without relevant adverse events and 100% overall survival. Clinical randomised trials are needed to confirm the clinical benefit of baricitinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
European journal of hospital pharmacy : science and practice - 29(2022), e1 vom: 28. März, Seite e41-e45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iglesias Gómez, Rubén [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Azetidines |
|---|
| Anmerkungen: |
Date Completed 09.03.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ejhpharm-2021-002741 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328659061 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328659061 | ||
| 003 | DE-627 | ||
| 005 | 20231225203414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ejhpharm-2021-002741 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328659061 | ||
| 035 | |a (NLM)34321249 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iglesias Gómez, Rubén |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baricitinib against severe COVID-19 |b effectiveness and safety in hospitalised pretreated patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis | ||
| 520 | |a METHODS: This was an observational retrospective study of hospitalised patients treated with baricitinib for severe COVID-19. Outcomes were clinical improvement on an ordinal scale of 1-8 on day 1 of baricitinib compared with day 14 (where 8=death and 1=not hospitalised with no limitations of activities), overall survival, time to recovery since baricitinib treatment started (days until hospital discharge) and laboratory parameters related to COVID-19 poor prognosis. Adverse events related to baricitinib during the admission period were also reported | ||
| 520 | |a RESULTS: Forty-three patients (70% men, mean age 70 years (IQR 54-79)) treated with baricitinib daily for 6 days (IQR 5-7) were included. Thirty-six patients were treated with corticosteroids (84%). Clinical improvement was 3 points (IQR 1-4) in patients on an ordinal scale of 4-6, overall survival was 100% at day 30 and day 60 with a mean time to recovery of 12 days (IQR 9-25) from start of baricitinib treatment. No adverse events of interest were found and all poor prognosis risk factors improved at day 14: interleukin-6, C-reactive protein, ferritin, lymphocytes, platelets and D-dimers | ||
| 520 | |a CONCLUSIONS: Patients treated with baricitinib for severe COVID-19 showed improvements in clinical and analytical values without relevant adverse events and 100% overall survival. Clinical randomised trials are needed to confirm the clinical benefit of baricitinib | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a critical care | |
| 650 | 4 | |a education | |
| 650 | 4 | |a evidence-based medicine | |
| 650 | 4 | |a pharmacy | |
| 650 | 4 | |a pulmonary medicine | |
| 650 | 4 | |a virology | |
| 650 | 7 | |a Azetidines |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a baricitinib |2 NLM | |
| 650 | 7 | |a ISP4442I3Y |2 NLM | |
| 700 | 1 | |a Méndez, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a Palanques-Pastor, Tomás |e verfasserin |4 aut | |
| 700 | 1 | |a Ballesta-López, Octavio |e verfasserin |4 aut | |
| 700 | 1 | |a Borrás Almenar, Conxa |e verfasserin |4 aut | |
| 700 | 1 | |a Megías Vericat, Juan Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a López-Briz, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Font-Noguera, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Menéndez Villanueva, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Román Iborra, José Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Poveda Andrés, José Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of hospital pharmacy : science and practice |d 2012 |g 29(2022), e1 vom: 28. März, Seite e41-e45 |w (DE-627)NLM225772213 |x 2047-9956 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:e1 |g day:28 |g month:03 |g pages:e41-e45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ejhpharm-2021-002741 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e e1 |b 28 |c 03 |h e41-e45 | ||